News
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...
Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...
The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...
“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results